ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Astellas Pharma, Inc. ?
1
High Management Efficiency with a high ROE of 6.28%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 42.73
3
With a growth in Net Sales of 17.12%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at JPY 566,251 MM
- NET PROFIT(HY) Higher at JPY 143,940 MM
- ROCE(HY) Highest at 17.45%
4
With ROE of 18.31%, it has a very attractive valuation with a 2.51 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 54.87%, its profits have risen by 662.2% ; the PEG ratio of the company is 0
- At the current price, the company has a high dividend yield of 0
5
Majority shareholders : FIIs
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Astellas Pharma, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Astellas Pharma, Inc. for you?
Low Risk, High Return
Absolute
Risk Adjusted
Volatility
Astellas Pharma, Inc.
54.87%
435.87
28.89%
Japan Nikkei 225
85.83%
3.09
27.80%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.46%
EBIT Growth (5y)
10.50%
EBIT to Interest (avg)
42.73
Debt to EBITDA (avg)
0.65
Net Debt to Equity (avg)
0.44
Sales to Capital Employed (avg)
0.73
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
261.05%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
15.78%
ROE (avg)
6.28%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
2.51
EV to EBIT
12.12
EV to EBITDA
8.22
EV to Capital Employed
2.19
EV to Sales
2.38
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
18.09%
ROE (Latest)
18.31%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend22What is working for the Company
OPERATING CASH FLOW(Y)
Highest at JPY 566,251 MM
NET PROFIT(HY)
Higher at JPY 143,940 MM
ROCE(HY)
Highest at 17.45%
DIVIDEND PER SHARE(HY)
Highest at JPY 3.04
DIVIDEND PAYOUT RATIO(Y)
Highest at 160.54%
RAW MATERIAL COST(Y)
Fallen by 0.32% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 21.36 %
NET SALES(Q)
At JPY 537,925 MM has Grown at 17.12%
-9What is not working for the Company
INTEREST(Q)
At JPY 3,035 MM has Grown at 24.08%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.73 times
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.04 times
OPERATING PROFIT MARGIN(Q)
Lowest at 23.83 %
PRE-TAX PROFIT(Q)
Lowest at JPY 48,172 MM
NET PROFIT(Q)
Lowest at JPY 43,617 MM
EPS(Q)
Lowest at JPY 24.2
Here's what is working for Astellas Pharma, Inc.
Operating Cash Flow
Highest at JPY 566,251 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (JPY MM)
Dividend per share
Highest at JPY 3.04 and Grown
In each year in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (JPY)
Net Sales
At JPY 537,925 MM has Grown at 17.12%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Debt-Equity Ratio
Lowest at 21.36 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Dividend Payout Ratio
Highest at 160.54%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Raw Material Cost
Fallen by 0.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 50,360 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Astellas Pharma, Inc.
Interest
At JPY 3,035 MM has Grown at 24.08%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Operating Profit Margin
Lowest at 23.83 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at JPY 48,172 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (JPY MM)
Net Profit
Lowest at JPY 43,617 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (JPY MM)
Net Profit
Fallen at -41.76%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (JPY MM)
EPS
Lowest at JPY 24.2
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (JPY)
Inventory Turnover Ratio
Lowest at 1.73 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debtors Turnover Ratio
Lowest at 3.04 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
